Loading..
  • SynAct Pharma logoSVE
  • SynAct Pharma logoENG
  • About us
    • The Company in brief
    • Vision
    • History
    • Organisation
    • New Partnerships
  • Our Science
    • Resolving Inflammation
    • Selective Melanocortin Stimulation
    • Scientific Advisory Board
  • Pipeline
    • Pipeline Overview
    • The AP1189 Development Program
    • Rheumatoid Arthritis
    • Membranous Nephropathy
    • Virus Induced Respiratory Insufficiency
    • Ongoing clinical studies
  • Investors
    • Listing Nasdaq 2022
    • Rights Issue 2022
    • Word from the CEO
    • Financial Reports
    • Investment highlights
    • Presentations
    • The Share
      • Share price development
      • Ownership Structure
      • Insiders
      • Share Capital Development
    • Analyst Coverage
    • Calendar
    • Press Releases
    • Prospectuses
  • Governance
    • General Meetings
    • Corporate Governance Report
    • Nomination Committee
      • Nomination Committee 2023
    • Board of Directors
      • Remuneration Committee
      • Audit Committee
    • Management
    • Auditor
    • Articles of Association
    • Code of Conduct
  • Media
    • Press Releases
    • Synact in Media
    • Image Bank
    • Subscribe
  • Contact

Press Releases

All releases
    • Regulatory
    • Non Regulatory
2017
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2016
  • All years
November 3, 2017
Regulatory

Interim report Q3 2017

October 6, 2017
Regulatory

CEO, CFO and CSO increase their shareholdings in SynAct

October 3, 2017
Regulatory

The first part of the clinical Phase I study with SynAct Pharma’s drug candidate AP1189 successfully completed

August 31, 2017
Regulatory

Half-yearly report 01-01-2017 – 30-06-2017

June 7, 2017
Regulatory

SynAct Pharma announces the start of Clinical Phase I study

May 11, 2017
Regulatory

Bulletin from the Annual General Meeting of SynAct Pharma AB (publ)

May 11, 2017
Regulatory

Interim report Q1 2017   Synact Pharma

May 10, 2017
Regulatory

SynAct Pharma AB receives approval to start Clinical Phase I study with AP1189 – a new potential treatment for psoriatic arthritis

April 27, 2017
Regulatory

Utilisation of subscription options registered with Swedish Companies Registration Office

April 25, 2017
Regulatory

SynAct Pharma AB provides an update on the clinical development plan for AP1189

April 20, 2017
Regulatory

Annual Report 2016

April 11, 2017
Regulatory

Notice of Annual General Meeting of SynAct Pharma AB (publ)

March 31, 2017
Regulatory

SynAct Pharma AB will raise 1,007,539.20 SEK through the utilisation of series TO 1 subscription options

March 17, 2017
Regulatory

Reminder of the utilisation of series TO 1 subscription options

March 9, 2017
Regulatory

SynAct Pharma AB retains subscription rights for series TO 1subscription option

March 9, 2017
Regulatory

The utilisation period of SynAct Pharma AB’s series TO 1 subscription options starts today

February 22, 2017
Regulatory

SynAct Pharma AB has received approval from the Ethics Committee and continues its dialogue with the French Medicines Agency

February 9, 2017
Regulatory

SynAct Pharma Year-end report 2016

January 27, 2017

SynAct presented in Copenhagen at Sedermera Investor Event

  • Media
    • Press Releases
    • Synact in Media
    • Image Bank
    • Subscribe

About Synact Pharma

SynAct Pharma is a clinical stage biotechnology company focused on resolving inflammation with melanocortin biology. Selective activation of the melanocortin system can help the immune system resolve excessive or chronic inflammation.

  • Privacy Policy
  • Cookies

Explore our Website

  • About us
  • Our Science
  • Pipeline
  • Investors
  • Governance
  • Media
  • Contact
  • LinkedIn

Subscribe